TSO3 — Investor Presentation (September 2016)
22 slides from TSO3's investor presentation, September 2016
Slide 1: Creating the Improved Standard in Healthcare Sterile Reprocessing
TSX:TOS Creating the Improved Standard in Healthcare Sterile Reprocessing™ Corporate Presentation September 2016
Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures
Important Cautions Regarding Forward Looking Statements and Other Disclosures TSX:TOS The statements in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts (including, without limitation, those regarding the timing
Slide 3: TSO3 - Our Vision
TSO3 - Our Vision TSX:TOS To Create the Improved Standard in Healthcare Sterile Reprocessing™ 3
Slide 4: Where We Are From and Where We Are Going
Where We Are From and Where We Are Going TSX:TOS 2016 • Record revenues 2009 - 2014 • Reworked products • Record assembly capacity • Introduced STERIZONE® 125L+ • US$21.3M in cash1 and VP4 Sterilizers • Extended FDA Claims for colonoscopes • Sterilizers sold and used in and other long flexible endos
Slide 5: Purpose
Purpose TSX:TOS A Sterile Device for Every Procedure 5
Slide 6: Multiple Large Target Markets
Multiple Large Target Markets TSX:TOS Existing Low-Temp Sterilizer Market Now Possible: Endoscopy/GI Market • Fastest growing sterilization segment (9%–10% CAGR1) • Expanded opportunity to terminally sterilize far more of the 55m+ annual procedures in US4 • Total equipment replacement value: $4.5 bi
Slide 7: Growing Demand for MIS & Endoscopy Procedures
Growing Demand for MIS & Endoscopy Procedures TSX:TOS Aging Recovery Bed Increasing Number of Minimally Invasive Surgeries Population Time Reduction (MIS) & Endoscopies Aging Population Expected to Drive Growth in MIS Surgeries and Endoscopies2 >30 million MIS procedures annually in the U.S.1 85+
Slide 8: Approach
Approach T at, TSX:TOS | [Propet \ f Pr est\ nnovation landyai re __ aries... Sterilizer Devices to All Patients
Slide 9: The Science – Patents Pending or Applied For
The Science – 36 Patents or Pending or Applied For TSX:TOS 9
Slide 10: STERIZONE VP4 Sterilizer
STERIZONE® VP4 Sterilizer TSX:TOS FDA-Cleared - Dual Sterilant, Low Temperature Sterilization System –With Multi-Channeled Flexible Scope Claim Advantages Dynamic Sterilant Delivery System™ • Single cycle – easy to use, error free cycle selection Proprietary Technology automatically adjusts the ster
Slide 11: Modernizing Healthcare Sterilization Technology
Modernizing Healthcare Sterilization Technology TSX:TOS Old Technology TSO3 Technology Low Temperature Sterilization Low Temperature Sterilization • 20+ year-old core technology The next generation industry technology • Operators must choose from several operating cycles Simple Single Cycle Oper
Slide 12: In Use
In Use TSX:TOS Mixed Loads Large Loads One Cycle 12
Slide 13: The Problem: Endoscopes & Superbugs
The Problem: Endoscopes & Superbugs TSX:TOS SUPERBUG = Antimicrobial Resistant Bacteria 2 million+ Americans suffer from antibiotic- resistant bacteria annually – 23,000 die1 CRE is resistant to most available antibiotics - up to 50% of infected patients die2 CRE infections increasingly prev
Slide 14: A Call For Action
A Call For Action TSX:TOS “Despite reprocessing in accordance with US guidelines, viable 55+ million endoscopic microbes and biologic debris persisted in clinically used [GI] procedures annually1 endoscopes, suggesting current reprocessing guidelines are not sufficient to ensure successful deconta
Slide 15: The Solution: FDA Clearance of Endoscope Claims
The Solution: FDA Clearance of Endoscope Claims TSX:TOS FDA has cleared the STERIZONE® VP4 July 2016: FDA cleared expanded indications Sterilizer for the sterilization of multi- for use of STERIZONE® VP4 Sterilizer to include: channeled flexible endoscopes (with a maximum of four channels) having
Slide 16: Commercialization
Commercialization TSX:TOS “The STERIZONE® VP4 Sterilizer Getinge Infection Control - exclusive global uniquely addresses an unmet global distributor to STERIZONE® VP4 Sterilizer need for cost effective, high throughput sterilization of complex medical devices Global sales & service - over 3,000
Slide 17: 1H 2016 Financial Highlights – USD
1H 2016 Financial Highlights – USD TSX:TOS Quarterly Revenues 50 STERIZONE® VP4 Sterilizers sold driving (US$ Millions) Q1 + Q2: Sold total of 50 record revenues of $6.1M in 1H 2016 STERIZONE® VP4 Sterilizers to Getinge Gross margin of 28-36%1, which indicates 3.1M $3.0M equipment margins and li
Slide 18: Key Stats (TSX: TOS)
Key Stats (TSX: TOS) All Dollars in USD, unless noted otherwise TSX:TOS Stock Price (9/1/16) CAD$3.07 Total Revenue (mrq) $3.0M Distributor (Getinge) 5-Year Sales Target 52 Week High-Low $1.42-$3.82 Gross Profit (mrq) $0.8M High-margin consumables and Avg. Daily Vol. (3 mo.) 0.3M Net Loss (mrq) $(1.
Slide 19: TSO3 Key Takeaways
TSO3 Key Takeaways TSX:TOS Razor/Razorblade recurring revenue business model with proprietary captive consumables. Industry changing technology that is selling now Global Distribution Partner Dual sterilant Dynamic Sterilant Delivery SystemTM Addressing multi-billion $ market opportunities
Slide 20: Contact Us
Contact Us TSX:TOS Investor Relations TSO3 Inc. - Canada Liolios Group, Inc. 2505, avenue Dalton Ron Both, Senior Managing Director Tel (949) 574-3860 Québec, Québec TOS@liolios.com G1P 3S5 CANADA Renmark Financial Communications Inc. Tel (418) 651-0003 Barry Mire, Vice President info@tso3.com Tel (
Slide 21: Appendix
Appendix +,
Slide 22: Regulatory Progression - Endoscopes
Regulatory Progression - Endoscopes TSX:TOS FDA is considering an expansion of its sterilization requirements1,2 Body Reprocessing FDA Device Class Highest Contact Requirements Today Signaled Sterile Body Sterilization Critical Critical Margin Cavity of Safety Mucous High Level Semi-Critical Critica